Wealth Enhancement Advisory Services LLC Trims Holdings in Moderna, Inc. (NASDAQ:MRNA)

Wealth Enhancement Advisory Services LLC lessened its position in Moderna, Inc. (NASDAQ:MRNA) by 29.8% in the third quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The fund owned 8,353 shares of the company’s stock after selling 3,541 shares during the period. Wealth Enhancement Advisory Services LLC’s holdings in Moderna were worth $558,000 as of its most recent SEC filing.

Several other institutional investors and hedge funds have also modified their holdings of MRNA. Janney Montgomery Scott LLC raised its holdings in Moderna by 38.6% in the 1st quarter. Janney Montgomery Scott LLC now owns 14,373 shares of the company’s stock valued at $1,532,000 after acquiring an additional 4,003 shares during the last quarter. Empirical Finance LLC lifted its position in Moderna by 4.7% during the first quarter. Empirical Finance LLC now owns 8,975 shares of the company’s stock worth $956,000 after buying an additional 399 shares during the period. Empowered Funds LLC lifted its position in Moderna by 26.8% during the first quarter. Empowered Funds LLC now owns 4,276 shares of the company’s stock worth $456,000 after buying an additional 904 shares during the period. SG Americas Securities LLC boosted its stake in Moderna by 32.8% in the 1st quarter. SG Americas Securities LLC now owns 79,310 shares of the company’s stock worth $8,451,000 after buying an additional 19,609 shares during the last quarter. Finally, Oppenheimer & Co. Inc. grew its holdings in Moderna by 25.6% in the 1st quarter. Oppenheimer & Co. Inc. now owns 40,305 shares of the company’s stock valued at $4,295,000 after buying an additional 8,214 shares during the period. Hedge funds and other institutional investors own 75.33% of the company’s stock.

Wall Street Analysts Forecast Growth

Several equities research analysts recently issued reports on MRNA shares. Barclays decreased their target price on shares of Moderna from $155.00 to $125.00 and set an “overweight” rating on the stock in a research report on Monday, September 16th. Leerink Partners decreased their price target on shares of Moderna from $60.00 to $48.00 and set an “underperform” rating on the stock in a report on Tuesday, September 17th. Needham & Company LLC restated a “hold” rating on shares of Moderna in a report on Friday, September 13th. Royal Bank of Canada reiterated a “sector perform” rating and issued a $75.00 target price on shares of Moderna in a report on Thursday, September 19th. Finally, JPMorgan Chase & Co. lowered their price target on Moderna from $70.00 to $59.00 and set an “underweight” rating for the company in a research report on Monday. Two research analysts have rated the stock with a sell rating, fourteen have given a hold rating and four have assigned a buy rating to the stock. According to data from MarketBeat, Moderna has an average rating of “Hold” and a consensus price target of $94.00.

Insider Activity

In related news, CFO James M. Mock sold 715 shares of Moderna stock in a transaction on Monday, October 7th. The shares were sold at an average price of $60.12, for a total transaction of $42,985.80. Following the sale, the chief financial officer now owns 9,505 shares of the company’s stock, valued at $571,440.60. The trade was a 0.00 % decrease in their position. The transaction was disclosed in a filing with the SEC, which is accessible through the SEC website. In other Moderna news, CFO James M. Mock sold 715 shares of the firm’s stock in a transaction that occurred on Monday, October 7th. The stock was sold at an average price of $60.12, for a total transaction of $42,985.80. Following the completion of the sale, the chief financial officer now owns 9,505 shares in the company, valued at $571,440.60. This trade represents a 0.00 % decrease in their position. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available through the SEC website. Also, CFO James M. Mock sold 1,321 shares of the company’s stock in a transaction that occurred on Wednesday, August 28th. The shares were sold at an average price of $79.39, for a total value of $104,874.19. Following the completion of the transaction, the chief financial officer now directly owns 8,600 shares in the company, valued at approximately $682,754. The trade was a 0.00 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Over the last three months, insiders sold 3,184 shares of company stock worth $238,531. 15.20% of the stock is currently owned by company insiders.

Moderna Stock Down 3.0 %

Shares of NASDAQ:MRNA opened at $50.28 on Friday. The company has a market capitalization of $19.33 billion, a price-to-earnings ratio of -3.27 and a beta of 1.69. The company has a 50 day moving average of $62.46 and a two-hundred day moving average of $99.62. Moderna, Inc. has a 52-week low of $49.60 and a 52-week high of $170.47. The company has a quick ratio of 3.92, a current ratio of 4.09 and a debt-to-equity ratio of 0.05.

About Moderna

Moderna, Inc, a biotechnology company, discovers, develops, and commercializes messenger RNA therapeutics and vaccines for the treatment of infectious diseases, immuno-oncology, rare diseases, autoimmune, and cardiovascular diseases in the United States, Europe, and internationally. Its respiratory vaccines include COVID-19, influenza, and respiratory syncytial virus, spikevax, and hMPV/PIV3 vaccines; latent vaccines comprise cytomegalovirus, epstein-barr virus, herpes simplex virus, varicella zoster virus, and human immunodeficiency virus vaccines; public health vaccines consists of Zika, Nipah, Mpox vaccines; and infectious diseases vaccines, such as lyme and norovirus vaccines.